Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

An automated, high-throughput method for standardizing image color profiles to improve image-based plant phenotyping.

Berry JC, Fahlgren N, Pokorny AA, Bart RS, Veley KM.

PeerJ. 2018 Oct 4;6:e5727. doi: 10.7717/peerj.5727. eCollection 2018.

2.

Simultaneous CRISPR/Cas9-mediated editing of cassava eIF4E isoforms nCBP-1 and nCBP-2 reduces cassava brown streak disease symptom severity and incidence.

Gomez MA, Lin ZD, Moll T, Chauhan RD, Hayden L, Renninger K, Beyene G, Taylor NJ, Carrington JC, Staskawicz BJ, Bart RS.

Plant Biotechnol J. 2019 Feb;17(2):421-434. doi: 10.1111/pbi.12987. Epub 2018 Oct 5.

3.

Genomics-enabled analysis of the emergent disease cotton bacterial blight.

Phillips AZ, Berry JC, Wilson MC, Vijayaraghavan A, Burke J, Bunn JI, Allen TW, Wheeler T, Bart RS.

PLoS Genet. 2017 Sep 14;13(9):e1007003. doi: 10.1371/journal.pgen.1007003. eCollection 2017 Sep.

4.

New opportunities and challenges to engineer disease resistance in cassava, a staple food of African small-holder farmers.

Bart RS, Taylor NJ.

PLoS Pathog. 2017 May 11;13(5):e1006287. doi: 10.1371/journal.ppat.1006287. eCollection 2017 May. Review. No abstract available.

5.

Cassava haplotype map highlights fixation of deleterious mutations during clonal propagation.

Ramu P, Esuma W, Kawuki R, Rabbi IY, Egesi C, Bredeson JV, Bart RS, Verma J, Buckler ES, Lu F.

Nat Genet. 2017 Jun;49(6):959-963. doi: 10.1038/ng.3845. Epub 2017 Apr 17.

PMID:
28416819
6.

Gene expression atlas for the food security crop cassava.

Wilson MC, Mutka AM, Hummel AW, Berry J, Chauhan RD, Vijayaraghavan A, Taylor NJ, Voytas DF, Chitwood DH, Bart RS.

New Phytol. 2017 Mar;213(4):1632-1641. doi: 10.1111/nph.14443. Epub 2017 Jan 24.

7.

Correction: A Genetic Screen Identifies a Requirement for Cysteine-Rich-Receptor-Like Kinases in Rice NH1 (OsNPR1)-Mediated Immunity.

Chern M, Xu Q, Bart RS, Bai W, Ruan D, Sze-To WH, Canlas PE, Jain R, Chen X, Ronald PC.

PLoS Genet. 2016 Jul 6;12(7):e1006182. doi: 10.1371/journal.pgen.1006182. eCollection 2016 Jul.

8.

A Genetic Screen Identifies a Requirement for Cysteine-Rich-Receptor-Like Kinases in Rice NH1 (OsNPR1)-Mediated Immunity.

Chern M, Xu Q, Bart RS, Bai W, Ruan D, Sze-To WH, Canlas PE, Jain R, Chen X, Ronald PC.

PLoS Genet. 2016 May 13;12(5):e1006049. doi: 10.1371/journal.pgen.1006049. eCollection 2016 May. Erratum in: PLoS Genet. 2016 Jul;12(7):e1006182.

9.

Sequencing wild and cultivated cassava and related species reveals extensive interspecific hybridization and genetic diversity.

Bredeson JV, Lyons JB, Prochnik SE, Wu GA, Ha CM, Edsinger-Gonzales E, Grimwood J, Schmutz J, Rabbi IY, Egesi C, Nauluvula P, Lebot V, Ndunguru J, Mkamilo G, Bart RS, Setter TL, Gleadow RM, Kulakow P, Ferguson ME, Rounsley S, Rokhsar DS.

Nat Biotechnol. 2016 May;34(5):562-70. doi: 10.1038/nbt.3535. Epub 2016 Apr 18.

PMID:
27088722
10.

Phylogenomics of Xanthomonas field strains infecting pepper and tomato reveals diversity in effector repertoires and identifies determinants of host specificity.

Schwartz AR, Potnis N, Timilsina S, Wilson M, Patané J, Martins J Jr, Minsavage GV, Dahlbeck D, Akhunova A, Almeida N, Vallad GE, Barak JD, White FF, Miller SA, Ritchie D, Goss E, Bart RS, Setubal JC, Jones JB, Staskawicz BJ.

Front Microbiol. 2015 Jun 3;6:535. doi: 10.3389/fmicb.2015.00535. eCollection 2015.

11.

Image-based phenotyping of plant disease symptoms.

Mutka AM, Bart RS.

Front Plant Sci. 2015 Jan 5;5:734. doi: 10.3389/fpls.2014.00734. eCollection 2014.

12.

Xanthomonas axonopodis virulence is promoted by a transcription activator-like effector-mediated induction of a SWEET sugar transporter in cassava.

Cohn M, Bart RS, Shybut M, Dahlbeck D, Gomez M, Morbitzer R, Hou BH, Frommer WB, Lahaye T, Staskawicz BJ.

Mol Plant Microbe Interact. 2014 Nov;27(11):1186-98. doi: 10.1094/MPMI-06-14-0161-R.

13.

Rice Snl6, a cinnamoyl-CoA reductase-like gene family member, is required for NH1-mediated immunity to Xanthomonas oryzae pv. oryzae.

Bart RS, Chern M, Vega-Sánchez ME, Canlas P, Ronald PC.

PLoS Genet. 2010 Sep 16;6(9):e1001123. doi: 10.1371/journal.pgen.1001123.

14.

Detection of melanomas in patients followed up with total cutaneous examinations, total cutaneous photography, and dermoscopy.

Wang SQ, Kopf AW, Koenig K, Polsky D, Nudel K, Bart RS.

J Am Acad Dermatol. 2004 Jan;50(1):15-20.

PMID:
14699359
15.

Management of Spitz nevi: a survey of dermatologists in the United States.

Gelbard SN, Tripp JM, Marghoob AA, Kopf AW, Koenig KL, Kim JY, Bart RS.

J Am Acad Dermatol. 2002 Aug;47(2):224-30.

PMID:
12140468
16.

Management of dysplastic nevi: a survey of fellows of the American Academy of Dermatology.

Tripp JM, Kopf AW, Marghoob AA, Bart RS.

J Am Acad Dermatol. 2002 May;46(5):674-82.

PMID:
12004306
17.

Ultraviolet A and melanoma: a review.

Wang SQ, Setlow R, Berwick M, Polsky D, Marghoob AA, Kopf AW, Bart RS.

J Am Acad Dermatol. 2001 May;44(5):837-46. Review.

PMID:
11312434
18.
19.

Large congenital melanocytic nevi and the risk for development of malignant melanoma and neurocutaneous melanocytosis.

Bittencourt FV, Marghoob AA, Kopf AW, Koenig KL, Bart RS.

Pediatrics. 2000 Oct;106(4):736-41.

PMID:
11015516
20.
21.

Laboratory tests and imaging studies in patients with cutaneous malignant melanoma.

Huang CL, Provost N, Marghoob AA, Kopf AW, Levin L, Bart RS.

J Am Acad Dermatol. 1998 Sep;39(3):451-63. Review.

PMID:
9738782
22.

Comparison of conventional photographs and telephonically transmitted compressed digitized images of melanomas and dysplastic nevi.

Provost N, Kopf AW, Rabinovitz HS, Stolz W, DeDavid M, Wasti Q, Bart RS.

Dermatology. 1998;196(3):299-304.

PMID:
9621136
23.

Predicting ten-year survival of patients with primary cutaneous melanoma: corroboration of a prognostic model.

Sahin S, Rao B, Kopf AW, Lee E, Rigel DS, Nossa R, Rahman IJ, Wortzel H, Marghoob AA, Bart RS.

Cancer. 1997 Oct 15;80(8):1426-31.

PMID:
9338466
24.

Laboratory tests and imaging studies in patients with cutaneous malignant melanomas: a survey of experienced physicians.

Provost N, Marghoob AA, Kopf AW, DeDavid M, Wasti Q, Bart RS.

J Am Acad Dermatol. 1997 May;36(5 Pt 1):711-20.

PMID:
9146532
25.

A study of large congenital melanocytic nevi and associated malignant melanomas: review of cases in the New York University Registry and the world literature.

DeDavid M, Orlow SJ, Provost N, Marghoob AA, Rao BK, Huang CL, Wasti Q, Kopf AW, Bart RS.

J Am Acad Dermatol. 1997 Mar;36(3 Pt 1):409-16. Review.

PMID:
9091472
26.

Can early malignant melanoma be differentiated from atypical melanocytic nevi by in vivo techniques?: Part I. Clinical and dermoscopic characteristics.

Rao BK, Marghoob AA, Stolz W, Kopf AW, Slade J, Wasti Q, Schoenbach SP, De-David M, Bart RS.

Skin Res Technol. 1997 Feb;3(1):8-14. doi: 10.1111/j.1600-0846.1997.tb00153.x.

PMID:
27333167
27.

Risk of developing multiple primary cutaneous melanomas in patients with the classic atypical-mole syndrome: a case-control study.

Marghoob AA, Slade J, Kopf AW, Salopek TG, Rigel DS, Bart RS.

Br J Dermatol. 1996 Nov;135(5):704-11.

PMID:
8977668
28.

Dermatoheliosis?

Bart RS.

J Am Acad Dermatol. 1996 Oct;35(4):649-50. No abstract available.

PMID:
8859309
29.

Neurocutaneous melanosis: clinical features of large congenital melanocytic nevi in patients with manifest central nervous system melanosis.

DeDavid M, Orlow SJ, Provost N, Marghoob AA, Rao BK, Wasti Q, Huang CL, Kopf AW, Bart RS.

J Am Acad Dermatol. 1996 Oct;35(4):529-38. Review.

PMID:
8859278
30.

Large congenital melanocytic nevi and the risk for the development of malignant melanoma. A prospective study.

Marghoob AA, Schoenbach SP, Kopf AW, Orlow SJ, Nossa R, Bart RS.

Arch Dermatol. 1996 Feb;132(2):170-5.

PMID:
8629825
31.

Management of cutaneous malignant melanoma by dermatologists of the American Academy of Dermatology. II. Definitive surgery for malignant melanoma.

Salopek TG, Slade JM, Marghoob AA, Rigel DS, Kopf AW, Bart RS, Friedman RJ.

J Am Acad Dermatol. 1995 Sep;33(3):451-61.

PMID:
7657869
32.

Management of cutaneous malignant melanoma by dermatologists of the American Academy of Dermatology. I. Survey of biopsy practices of pigmented lesions suspected as melanoma.

Salopek TG, Slade J, Marghoob AA, Rigel DS, Kopf AW, Bart RS, Friedman RJ.

J Am Acad Dermatol. 1995 Sep;33(3):441-50.

PMID:
7657868
33.

An estimate of the incidence of malignant melanoma in the United States. Based on a survey of members of the American Academy of Dermatology.

Salopek TG, Marghoob AA, Slade JM, Rao B, Rigel DS, Kopf AW, Bart RS.

Dermatol Surg. 1995 Apr;21(4):301-5.

PMID:
7728479
34.

Atypical mole syndrome: risk factor for cutaneous malignant melanoma and implications for management.

Slade J, Marghoob AA, Salopek TG, Rigel DS, Kopf AW, Bart RS.

J Am Acad Dermatol. 1995 Mar;32(3):479-94. Review.

PMID:
7868720
35.

Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications.

Marghoob AA, Slade J, Salopek TG, Kopf AW, Bart RS, Rigel DS.

Cancer. 1995 Jan 15;75(2 Suppl):707-14.

PMID:
7804999
36.

Techniques of cutaneous examination for the detection of skin cancer.

Kopf AW, Salopek TG, Slade J, Marghoob AA, Bart RS.

Cancer. 1995 Jan 15;75(2 Suppl):684-90.

PMID:
7804995
37.

Risk of cutaneous malignant melanoma in patients with 'classic' atypical-mole syndrome. A case-control study.

Marghoob AA, Kopf AW, Rigel DS, Bart RS, Friedman RJ, Yadav S, Abadir M, Sanfilippo L, Silverman MK, Vossaert KA.

Arch Dermatol. 1994 Aug;130(8):993-8.

PMID:
8053716
38.

Follow-up recommendations for patients with stage I malignant melanoma.

Romero JB, Stefanato CM, Kopf AW, Bart RS.

J Dermatol Surg Oncol. 1994 Mar;20(3):175-8.

PMID:
8151030
39.

Solar nevogenesis: a surrogate for predicting a rise in incidence of malignant melanoma because of ozone depletion.

Stefanato CM, Romero JB, Kopf AW, Bart RS.

J Am Acad Dermatol. 1993 Sep;29(3):486-7. No abstract available.

PMID:
8053993
40.

Risk of another basal cell carcinoma developing after treatment of a basal cell carcinoma.

Marghoob A, Kopf AW, Bart RS, Sanfilippo L, Silverman MK, Lee P, Levy E, Vossaert KA, Yadav S, Abadir M.

J Am Acad Dermatol. 1993 Jan;28(1):22-8.

PMID:
8425966
41.

Hypopigmented macules. Hypopigmented mycosis fungoides (MF).

Cooper D, Jacobson M, Bart RS.

Arch Dermatol. 1992 Sep;128(9):1266-7, 1269-70. No abstract available.

PMID:
1519945
42.

Recurrence rates of treated basal cell carcinomas. Part 4: X-ray therapy.

Silverman MK, Kopf AW, Gladstein AH, Bart RS, Grin CM, Levenstein MJ.

J Dermatol Surg Oncol. 1992 Jul;18(7):549-54.

PMID:
1624628
43.

Recurrence rates of treated basal cell carcinomas. Part 3: Surgical excision.

Silverman MK, Kopf AW, Bart RS, Grin CM, Levenstein MS.

J Dermatol Surg Oncol. 1992 Jun;18(6):471-6.

PMID:
1592998
44.

Influence of gender on survival in patients with stage I malignant melanoma.

Vossaert KA, Silverman MK, Kopf AW, Bart RS, Rigel DS, Friedman RJ, Levenstein M.

J Am Acad Dermatol. 1992 Mar;26(3 Pt 2):429-40. Review.

PMID:
1564150
45.

Level of education and the risk of malignant melanoma.

Lee PY, Silverman MK, Rigel DS, Vossaert KA, Kopf AW, Bart RS, Garfinkel L, Levenstein MJ.

J Am Acad Dermatol. 1992 Jan;26(1):59-63.

PMID:
1732337
46.

Clinical features of dysplastic nevi.

McBride A, Rivers JK, Kopf AW, Cockerell CJ, Bart RS, Grin CM, Silverman MK, Vossaert KA.

Dermatol Clin. 1991 Oct;9(4):717-22.

PMID:
1934646
47.

Volume of malignant melanoma is superior to thickness as a prognostic indicator. Preliminary observation.

Friedman RJ, Rigel DS, Kopf AW, Grin CM, Heilman E, Bart RS, Kamino H, Harris MN, Roses DF, Postel AH, et al.

Dermatol Clin. 1991 Oct;9(4):643-8.

PMID:
1934639
48.

Recurrence rates of treated basal cell carcinomas. Part 1: Overview.

Silverman MK, Kopf AW, Grin CM, Bart RS, Levenstein MJ.

J Dermatol Surg Oncol. 1991 Sep;17(9):713-8.

PMID:
1890243
49.

Recurrence rates of treated basal cell carcinomas. Part 2: Curettage-electrodesiccation.

Silverman MK, Kopf AW, Grin CM, Bart RS, Levenstein MJ.

J Dermatol Surg Oncol. 1991 Sep;17(9):720-6.

PMID:
1820764
50.

Late recurrence of malignant melanoma: a report of five cases, a review of the literature and a study of associated factors.

Levy E, Silverman MK, Vossaert KA, Kopf AW, Bart RS, Golomb FM, Levenstein MJ.

Melanoma Res. 1991 Apr-May;1(1):63-7. Review.

PMID:
1822771

Supplemental Content

Support Center